Posted on 9/22/16
The Most Exciting Drug in Celgene's Pipeline
IMAGE SOURCE: PIXABAY.Seeing as it contributes more than 60% of total revenue, it is no surprise that $6 billion blood cancer drug Revlimid has captured the . . .
Posted on 9/16/16
5 Reasons Celgene Is a Buy
IMAGE SOURCE: CELGENE While the past few months have been good to Celgene (NASDAQ:CELG) investors, shares are still down about 11% year to date, dramatically underperforming . . .
New York
